General Orthopaedics
Extended-release metoprolol in the prevention of CV complications in non-cardiac surgery
Lancet. 2008 May 31;371(9627):1839-47. doi: 10.1016/S0140-6736(08)60601-7. Epub 2008 May 12.9298 patients with, or at risk of, atherosclerotic disease and undergoing non-cardiac surgery, were randomized to receive perioperative administration of either extended-release metoprolol or a placebo equivalent. The purpose of this study was to compare these two groups with respect to rates of cardiovascular complications over a period of 30 postoperative days. Results indicated that, although the metoprolol group experienced significantly lower rates of fatal and non-fatal myocardial infarction, cardiac revascularisation and new clinically-significant atrial fibrillation, the proportion of patients who either died (total mortality), suffered a stroke or experienced clinically-significant hypotension and bradycardia was significantly lower in the placebo group.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
